



Cornerstone Pharmaceuticals, Inc  
1 Duncan Drive  
Cranbury, NJ 08512

Media Contact: Meghan Weber  
Liza Sullivan & Associates  
(917) 399-8713

## **CORNERSTONE PHARMACEUTICALS CHOSEN AMONG TOP 10 MOST INTERESTING ONCOLOGY PROJECTS**

**Cranbury, NJ, November 11, 2009** – Cornerstone Pharmaceuticals, Inc., the company behind CPI-613 - the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes that may be common to many cancer types - has been selected as one of the top 10 most interesting oncology projects available for partnering by Windhover Information, a provider of analysis of the healthcare industry to decision-makers at all levels for over 25 years.

As part of being selected, Cornerstone Pharmaceuticals President & COO Robert Rodriguez will present at Windhover's Therapeutic Area Partnerships meeting on November 17-19, 2009 at the Westin Copley Boston.

"We are very proud to have CPI-613 selected by Windhover as one of the top 10 most interesting oncology projects and look forward to the potential partnerships stemming from this distinction," remarked Cornerstone Pharmaceuticals CEO Dr. Robert Shorr. "It's also very exciting to have Bob Rodriguez, our President and COO, represent us at the upcoming meeting in Boston and I expect he will deliver an exceptional address."

Cornerstone is currently in the midst of recruiting patients with solid tumors to advance multiple Phase I/II human clinical trials of CPI-613, its lead drug to emerge from the company's Altered Energy Metabolism Directed (AEMD) technology platform. Trials are in progress both in the United States and in British Columbia, Canada.

Windhover selected and screened companies using a strict set of judging criteria for the Top 10 award representing what their committees considered the most attractive oncology opportunities the industry has to offer. Among the rigorous criteria Cornerstone Pharmaceuticals adhered to were: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.

"We are thrilled that Cornerstone Pharmaceuticals' CPI-613 project achieved those high standards," added Shorr.

### **About TA Partnerships**

Windhover Information's 4th Annual Therapeutic Area Partnerships is the industry's most targeted and efficient partnering meeting for life science companies seeking partnerships in the



top therapeutic areas: Oncology, Cardiovascular/Metabolic, Neuroscience and Inflammatory Diseases. Decision-makers (business development and R & D) focusing on these therapeutic categories can meet to develop strategic alliances between their companies. Also, attendees enjoy the personal and interactive setting that combines company presentations, 1:1 meetings and networking functions.

### **About Windhover**

Windhover Information Inc., an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see [www.windhover.com](http://www.windhover.com).

### **About CPI-613**

CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes that may be common to many cancer types. Cornerstone Pharmaceuticals is currently recruiting patients with solid tumors to advance multiple Phase I/II human clinical trials of CPI-613, CPI-613 is being evaluated in a Phase I/II single agent trial for patients who have failed all other therapy as well as in a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients determined to be treated with gemcitabine. Pancreatic cancer, like many solid tumors, typically has a poor prognosis, spreads rapidly and often goes undetected in its early stages. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.

### **About Cornerstone Pharmaceuticals**

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. Cornerstone is the only company that currently has a drug in clinical trials targeting certain key enzymes crucial to cancer cell metabolism. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated. Its lead drug, CPI-613, is currently being evaluated in three ongoing Phase I and Phase I/II clinical trials in a variety of tumor types. For further information, visit <http://www.cornerstonepharma.com>. Or contact: Meghan Weber at (917) 399-8713.

# # #

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such



statements should not be regarded as a representation by the company, or any other person, that such forwardlooking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.